milnacipran has been researched along with Kidney Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brand-Schieber, E; Chen, L; Ghahramani, P; Greenberg, WM; Periclou, A; Wangsa, J | 1 |
| Leonard, BE; Puozzo, C | 1 |
1 review(s) available for milnacipran and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetics of milnacipran in comparison with other antidepressants.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biological Availability; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Half-Life; Humans; Kidney Diseases; Liver Diseases; Metabolic Clearance Rate; Milnacipran; Selective Serotonin Reuptake Inhibitors; Tissue Distribution | 1996 |
1 trial(s) available for milnacipran and Kidney Diseases
| Article | Year |
|---|---|
Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Topics: Administration, Oral; Adult; Aged; Antidepressive Agents; Area Under Curve; Chemistry, Pharmaceutical; Chromatography, Liquid; Cyclopropanes; Delayed-Action Preparations; Female; Half-Life; Humans; Kidney; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged; Milnacipran; Renal Elimination; Serotonin and Noradrenaline Reuptake Inhibitors; Severity of Illness Index; Tandem Mass Spectrometry; United States | 2015 |